Parveen Malhotra

Hepatitis-2015Orlando, USA

July 20 - 22 2015

Dr. PARVEEN MALHOTRA

MD,DNB (GASTRO),MNAMS,FIACM,FICP,PGDD

PROFESSOR & HEAD

DEPTT. OF MEDICAL GASTROENTEROLOGY

PGIMS, ROHTAK

THE CULPRIT- NO VACCINATION

REAL CAUSE FOR FIGHT

Source: Sentinel Counties, CDC

Sources of Infection for Persons with Hepatitis C

Sexual 15%Sexual 15%

Other* 5%Other* 5%

Unknown 10%Unknown 10%Injecting Injecting drug use 60%drug use 60%

Transfusion 10%Transfusion 10%(before screening)(before screening)

**Nosocomial; Nosocomial; Health-care work; Health-care work; PerinatalPerinatal

Source: Centers for Disease Control and Prevention

Indian Scenario

Nearly 12.5 million Indians are suffering from Hepatitis C affecting the liver.

Over one lakh people get infected every year in India, according to the Indian National Association for the Study of Liver (INASL) study.

Every 15th carrier of the HCV is an Indian, according to a recent report and it is responsible for as many as one in four cases of liver cancer and chronic liver disease.

HARYANA SCENARIOInitially in Haryana , the prevalence of Chronic

hepatitis C was thought to be comparable to other parts of India.

Now the prevalence has drastically increased and is reaching the levels of areas with high incidence like Manipur and Punjab.

There are certain districts like Jind , Kaithal, Fatehabad, Panipat, Karnal and Sonepat where Prevalence is touching even 40-50%.

GOOD NEWS FOR HARYANA Haryana has become the first state of India

where a separate, dedicated centre has been started under Department of Medical Gastroenterology, PGIMS, Rohtak.

Free treatment of Chronic Hepatitis C has been

started for patients belonging to BPL/SC and at subsidized rates for general population.

 Twenty thousand patients have been screened over different parts of haryana.

HEALTH TALKS

HEALTH LECTURES

MEDIA INTERACTIONS

BILONA VILLAGE

AWARENESS TALK AT DERAS

DHABI TEK SINGH VILLAGE

Patients were treated with standard doses of Pegylated Interferon and Ribavarin.

Up till now 1500 patients have completed treatment.

At present 1500 more patients are currently on treatment.

GENDER DISTRIBUTION

DEMOGRAPHICAL PROFILE

MARITAL STATUS

AGE DISTRIBUTION

DISTRICT WISE DISTRIBUTION

RISK FACTORS

SYMPTOMATOLOGY

GENOTYPE DISTRIBUTION

SIDE EFFECTS

VIROLOGICAL RESPONSE

Type of report% patients negative on HCV RNA report

4th week HCV RNA 60%

12th week HCV RNA 92%

End of therapy (24/48 weeks) 96%

Sustained Virological Response (SVR)

90%

COMPLIANCE RATE

Therapy adherence n %

Total enrolled patients 1500 100%

Total adherent among all enrolled patients

1402 93.46%

Total non-adherent among all enrolled patients

98 6.54%

HEPATITIS C HELPLINE 08950012900

CHEER LEADERS

CHEER COUPLE

ACTIVE ROLE OF NGO’S

AWARENESS BY STAFF

MOTIVATION FROM TOP

SOFOSBUVIR- A NEW HOPEUp till now 200 patients have been put on

treatment

Majority are on Triple therapy

Dual therapy – Decompensated cirrhotic or on patient will

RVR has been achieved in 95% of patients

Excellent Compliance rate

CONCLUSIONSHaryana has become new hub of Chronic hepatitis C

in India.Majority of patients are male and belong to young

age group i.e. 20-40 years of age group.Genotype 3 most common and Genotype 4 is more

common in comparison to other parts of Northern India.

Most common side effects- A.N. & Depression, Dyspepsia, Weight loss, Malaise, Generalized weakness.

Good compliance and success rates are being achieved.

TAKE HOME MESSAGEMost important and first step is appreciation of

problem.Next step is to prioritize resources in more

prevalent areas.Development of Vaccine and Interferon free

regimen is future dream for hepatitis C.Regular Screening camps and awareness in

society is utmost need of hour to curb the menace of this disease.

Do not wait till all resources are compiled- Start moving.

RATIONALE BASED TREATMENTPseudo belief on Alternative Medicines.Anti HCV Vs HCV RNA based

ECONOMICAL TREATMENT STRATEGIESSCIENTIFIC AND RATIONALE BASED TREATMENT

ROLE OF TREATING PHYSICIANS

ROLE OF STATE AND CENTER

ROLE OF NGO’S

ROLE OF PHARMACEUTICAL COMPANIES

ROLE OF MEDIA AND GENERAL POPULATION

Hepatitis– 2016 Website:

hepatitis.omicsgroup.com

Meet the eminent gathering once again at

Hepatitis-2016Dubai, UAE

October 17 - 19, 2016